Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Amarin Corporation plc AMRN
$1.22
+$0.04 (3.39%)
На 18:00, 12 мая 2023
+77.87%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
491181307.00000000
-
week52high
2.23
-
week52low
1.04
-
Revenue
369193000
-
P/E TTM
-6
-
Beta
1.79134900
-
EPS
-0.27000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 12:00
Описание компании
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Sell | Sell | 24 мая 2022 г. |
| JP Morgan | Underweight | Neutral | 06 мая 2022 г. |
| SVB Leerink | Market Perform | Outperform | 05 мая 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 05 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 16 февр 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 19 окт 2022 г. |
| Jefferies | Buy | Hold | 06 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Stewart Murray | A | 182433 | 182433 | 09 янв 2023 г. |
| Stewart Murray | A | 223560 | 223560 | 09 янв 2023 г. |
| Ketchum Steven B | D | 47766 | 47767 | 30 дек 2022 г. |
| Ketchum Steven B | D | 544021 | 16361 | 30 дек 2022 г. |
| Ketchum Steven B | A | 560382 | 47767 | 30 дек 2022 г. |
| Berg Aaron | D | 47766 | 47767 | 30 дек 2022 г. |
| Berg Aaron | D | 451180 | 16361 | 30 дек 2022 г. |
| Berg Aaron | A | 467541 | 47767 | 30 дек 2022 г. |
| Mikhail Karim | D | 11366 | 11367 | 30 дек 2022 г. |
| Mikhail Karim | D | 114784 | 1270 | 30 дек 2022 г. |
Новостная лента
Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall
Zacks Investment Research
03 мая 2023 г. в 15:13
Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
Zacks Investment Research
02 мая 2023 г. в 14:32
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
GlobeNewsWire
19 апр 2023 г. в 08:00
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President & CEO, and members of Amarin's senior management team to discuss the Company's first quarter 2023 financial results on Wednesday, May 3rd, 2023 at 8:00 a.m. ET.
Amarin: Sarissa Has Control, But Amarin Will Need Patience
Seeking Alpha
16 апр 2023 г. в 09:15
Sarissa Capital has taken full control of Amarin. The previous management was doing some slow but decent work, but did not get time to show results.
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
The Motley Fool
04 апр 2023 г. в 15:53
Two economic reports point to a possible recession later this year. Investors sold off risky biotech stocks as a result.